Common heart medication less effective in Bangladeshi people – new research

google news icon

Common heart medication less effective in Bangladeshi people

Clopidogrel, a drug that lowers the chance of having another heart attack, is frequently administered to those who have recently experienced a heart attack. Although the medication is incredibly efficient at preventing further heart attacks, it can only do so when the CYP2C19 enzyme in the body activates it. Because the body can’t produce this enzyme due to certain genetic differences, clopidogrel cannot be activated by the body.

Clopidogrel not activating is actually a pretty frequent occurrence. According to estimates, one in three persons with European ancestry have one of these genetic variations; in certain ethnic groups, their prevalence is significantly higher.

For instance, one of these genetic variations is present in over 90% of Indigenous people living on Pacific island nations. They therefore most likely have a higher risk of having another heart attack if clopidogrel is administered. There haven’t been many non-European population studies that connect genetic variations with actual health data, though.

Additionally, our most recent research suggests that many British south Asians may not benefit from clopidogrel. This is noteworthy since south Asian populations in the UK have high incidence of cardiovascular disease.

Genetic variants
We began our study by analysing data from 44,396 participants who’d participated in Genes & Health – a study of British-Pakistani and British-Bangladeshi people, which has linked genetic data with national records of health problems and prescriptions.


We found that nearly six in every ten people (57%) had a genetic marker that meant they would not be able to activate clopidogrel well – much higher than the 30-35% seen in people of European ancestry. Some 13% of the British-Pakistani and British-Bangladeshi people in the study had two of these genetic markers – one from each parent.

From the 44,396 participants in the study, we identified 1,006 people who had experienced a heart attack. Of these, around 69% (697 people) were prescribed clopidogrel by their GP. The majority of these participants were male.

We then sub-stratified this group by CYP2C19 genotype, and looked at participants who’d suffered recurrent heart attacks. We found that participants with recurrent heart attacks were more than three times more likely to have two clopidogrel-resistance genes as compared with none.

Genetic testing
Our study isn’t the first to suggest that clopidogrel may not be as effective for people from different ethnic groups – but it is the first to link genetic risk for decreased clopidogrel efficacy with recurrent heart attacks in a western south Asian population.

These results reiterate the importance of testing drugs on people from many different ethnic backgrounds. During its development, clopidogrel was mainly tested using people of European ancestry. This gave a skewed view of its effectiveness, especially for certain ethnic groups.

Our study also highlights the role that genetic testing can play when it comes to prescribing. Knowing what genetic variants a person has will help ensure they’re prescribed a drug that is not only effective for them, but that has minimal risk of side-effects.

Genetic testing is already available on the NHS by referral, but it is typically only done to determine a person’s risk of certain health conditions. While there are plans to offer genetic testing to stroke patients to determine if clopidogrel will work for them (the drug is also used to prevent recurrent strokes), our study suggests that expanding this genetic testing to heart attack patients would also be beneficial.

Although people in certain groups have a higher chance of having these genetic variants, it’s important to take your medication as prescribed. Clopidogrel use is still well supported by clinical evidence to prevent further heart attacks – and genetic variations are only one of many factors that affect the risks and benefits of a medication.


Next Post

Market profile: Bangladesh is a growth enabler

Thu Aug 31 , 2023
Follow us on Google News to get latest news Bangladesh is occasionally disregarded as a crucial differential student recruiting market for enabling expansion and diversity, even if Nepal and Bhutan are frequently mentioned as exciting growth areas. With 12,700 students registered in British universities, Bangladesh has become one of the […]
Bangladesh is a growth enabler

You May Like

Subscribe Our Newsletter

Daily Dazzling Dawn is the first and only international and non-profitable newspaper, which is 100% ownership of professional journalists from Bangladeshi origin with 20 years of experience in global journalism. The main aim of the newspaper is promoting ethical journalism with truth, accuracy and proficiency.

Editor in Chief

Dulal Ahmed Chowdhury

Dulal Ahmed Chowdhury is the Editor of The Daily Dazzling Dawn. Previously, he has been serving in important positions in all the famous national dailies of the Bangladesh since the nineties. He has played a commendable role in journalism by participating in various events at the national and international levels. United Nations Conference, World Climate Conference, SAARC Summit are notable among them.

Quick Jump

error: Content is protected !!